NCT03113162

Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis

Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 15 (estimated)
• Sponsor: Makati Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a patient-sponsored study that evaluates the safety and efficacy of reduced-intensity immunoablation followed by a single dose autologous hematopoetic stem cell transplantation in patients diagnosed with multiple sclerosis. Patients are followed-up after 1 month, 3 months, 6 months and 12 months post-transplantation.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
BIOLOGICAL	Autologous Hematopoietic Stem Cell
DRUG	BEAM Regimen	Reduced-intensity BEAM for Immunoablation

Timeline

• Start date: 2015-05-29
• Primary completion: 2020-05-29
• Completion: 2022-05-29
• First posted: 2017-04-13
• Last updated: 2017-05-05

Locations

1 site across 1 country: Philippines